Nova Pharmaceuticals Australasia PT Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Nova Pharmaceuticals Australasia PT Pharmaceutical Import Records from India — 3 Products, $2.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nova Pharmaceuticals Australasia PT — Pharmaceutical Importer Profile (2026) | 3 Products, $2.0M Trade | TransData Nexus

Nova Pharmaceuticals Australasia PT

Pharmaceutical Importer · Australia · Brand Names & OTC Products Focus · $2.0M Total Trade · DGFT Verified

Nova Pharmaceuticals Australasia PT is a pharmaceutical importer based in Australia with a total trade value of $2.0M across 3 products in 3 therapeutic categories. Based on 57 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Nova Pharmaceuticals Australasia PT sources from 8 verified Indian suppliers, with Marksans Pharma Limited accounting for 46.3% of imports.

Nova Pharmaceuticals Australasia PT — Import Portfolio & Supplier Network

Nova Pharmaceuticals Australasia PT import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Nova Pharmaceuticals Australasia PT?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Marksans Pharma Limited	$4.7M	229	46.3%
V S International Private Limited	$2.0M	111	20.0%
Mepro Pharmaceuticals Private Limited

What Formulations Does Nova Pharmaceuticals Australasia PT Import?

Formulation	Value	Ships
Anaesthetic lozenges - betadine	$558.7K	14
Ibuprofen soft gelatin capsules 200 MG	$417.8K	12
Coles ibuprofen tablets 200 MG	$247.0K	6
Ibuprofen round shaped tabs BP 200MG	$234.4K	7
Hedafen ibuprofen round shaped tablets 200 MG	$193.9K	6
Ibuprofen round shaped tabs BP 200MG	$175.1K	4
Anaesthetic lozenges - betadine	$164.6K	4
Paracetamol tablets 500MG batch no	$146.6K	4
Inhalers - coles	$135.7K	5
Pharmaceutical products-paracetamol TAB	$115.5K	6
Pharmaceutical products-paracetamol	$109.2K	4
Paracetamol tablets BP 500MG batch no	$106.1K	6
Inhalers - medichoice	$99.8K	4
Hedafen ibuprofen round shaped tablets 200 MG	$95.4K	3
Ibuprofen soft gelatin capsules 200MG	$88.8K	2

Nova Pharmaceuticals Australasia PT imports 293 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Betadine	Brand Names & OTC Products	$1.4M	41	19.0%	2
2	Melatonin	Nutritional Supplements	$267.9K	9	2.9%	8
3	Methylprednisolone	Corticosteroids	$257.0K	7	0.9%	17

Nova Pharmaceuticals Australasia PT imports 3 pharmaceutical products across 3 categories into Australia totaling $2.0M.

Nova Pharmaceuticals Australasia PT — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Nova Pharmaceuticals Australasia Pty Ltd, established in 2003 in Sydney, Australia, is a privately owned, innovative pharmaceutical company. Over the past two decades, it has become a leading supplier of medicinal products to Australian pharmacies and supermarkets, including major chains such as Coles, Woolworths, Aldi, and Metcash. (novapharm.com.au) The company's diverse portfolio encompasses prescription and over-the-counter (OTC) medications, catering to a wide range of therapeutic categories.

In 2019, Nova Pharmaceuticals expanded its presence in the pharmacy sector by launching its own product range, which is now available in 3,885 pharmacies nationwide. This strategic move has positioned the company as one of the fastest-growing entities within Australia's OTC pharmaceutical market. (novapharm.com.au) Key brands include Glucoboost, Bubs & Co, Elactalyte, and MediChoice Eucalyptus Spray. The company's vision is to make a meaningful difference in people's lives by providing access to quality medicine at affordable prices. (novapharm.com.au)

2Distribution Network

Nova Pharmaceuticals operates from its headquarters at 10 Norbrik Drive, Bella Vista, New South Wales 2153, Australia. (novapharm.com.au) While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive distribution network ensures that its products are available across Australia. This widespread availability is facilitated through partnerships with major pharmacy wholesalers and supermarket chains, enabling efficient delivery to pharmacies and retail outlets nationwide.

3Industry Role

Nova Pharmaceuticals Australasia Pty Ltd functions primarily as a pharmaceutical importer and distributor within Australia's supply chain. By sourcing a broad range of medicinal products, including prescription and OTC medications, the company plays a crucial role in ensuring the availability of diverse pharmaceutical options to Australian consumers. Its strategic partnerships with both international and local suppliers underscore its position as a key player in the pharmaceutical distribution sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Nova Pharmaceuticals Australasia PT

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Nova Pharmaceuticals' sourcing strategy exhibits a significant concentration on a select group of suppliers. The company's total import value from India amounts to $2.0 million USD, distributed across 57 shipments and 293 unique formulations. The top five products imported from India include Betadine ($1.4 million, 19.0% share), Melatonin ($268K, 2.9% share), and Methylprednisolone ($257K, 0.9% share). This concentration indicates a strategic choice to focus on specific high-demand products, potentially streamlining operations and strengthening supplier relationships.

The shipment data reveals a stable relationship with key Indian suppliers, such as Marksans Pharma Limited, V S International Private Limited, and Mepro Pharmaceuticals Private Limited. This stability suggests a reliable supply chain, reducing the risks associated with supplier dependency. However, the lack of diversification in sourcing could pose challenges if any of these suppliers face operational disruptions or regulatory issues.

2Supply Chain Resilience

Nova Pharmaceuticals' supply chain resilience is closely tied to its reliance on a limited number of Indian suppliers. While this focus allows for streamlined operations, it also means that any disruptions with these suppliers could significantly impact Nova's product availability. The company's import data indicates a diverse range of formulations, which may help mitigate risks associated with product-specific supply chain issues. However, the overall resilience is contingent upon the operational stability and regulatory compliance of its key suppliers.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of pharmaceutical imports is overseen by the Therapeutic Goods Administration (TGA), which operates under the Therapeutic Goods Administration Act 1989. This legislation establishes the framework for the regulation of therapeutic goods, including medicines, to ensure their quality, safety, and efficacy. The TGA's responsibilities encompass the evaluation, monitoring, and regulation of therapeutic goods, as well as the enforcement of compliance with Australian standards.

2Import Licensing & GMP

Importers of pharmaceutical products into Australia must comply with the TGA's requirements, which include obtaining an import license and ensuring that imported goods meet Good Manufacturing Practice (GMP) standards. The TGA recognizes GMP certifications from various international bodies, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the importation of pharmaceutical products from countries with established GMP standards, such as India.

3Quality & Labeling

Nova Pharmaceuticals Australasia PT — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Nova Pharmaceuticals Australasia Pty Ltd's focus on specific therapeutic areas, such as Brand Names & OTC Products, Nutritional Supplements, and Corticosteroids, aligns with market demand and consumer preferences. The company's import data indicates a significant emphasis on Betadine, a topical antiseptic, and Melatonin, a supplement commonly used for sleep disorders. This strategic focus allows Nova to cater to prevalent health concerns and capitalize on high-demand products within the Australian market.

2Sourcing Profile

Nova Pharmaceuticals' sourcing strategy is centered on importing finished pharmaceutical formulations from India, particularly in the categories of Brand Names & OTC Products, Nutritional Supplements, and Corticosteroids. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. By focusing on finished products, Nova can streamline its supply chain and ensure consistent product quality, meeting the needs of the Australian market effectively.

3Market Positioning

Based on its product mix, Nova Pharmaceuticals Australasia Pty Ltd serves multiple segments of the Australian pharmaceutical market, including retail pharmacies, supermarkets, and potentially hospital and government tenders. The company's extensive distribution network and diverse product portfolio enable it to cater to a wide range of consumer needs, positioning Nova as a versatile and accessible pharmaceutical supplier across various channels.

Seller's Guide — How to Become a Supplier to Nova Pharmaceuticals Australasia PT

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Nova Pharmaceuticals Australasia Pty Ltd. By offering high-quality, GMP-compliant products in the therapeutic areas that Nova focuses on, Indian exporters can meet the company's sourcing needs. Additionally, providing competitive pricing and reliable delivery schedules can enhance the attractiveness of these suppliers. However, potential suppliers must be prepared to navigate Australia's regulatory requirements and ensure that their products meet the necessary standards for importation.

2Requirements & Qualifications

Indian exporters aiming to supply Nova Pharmaceuticals Australasia Pty Ltd and the Australian market must ensure that their products comply with the TGA's regulations. This includes obtaining GMP certifications recognized by the TGA, such as those from the EU, WHO, or PIC/S. Products must also meet Australian labeling requirements, including accurate English labeling with all necessary information. Additionally, exporters should be prepared to provide batch testing data and stability studies to demonstrate product quality and safety.

3How to Approach

Frequently Asked Questions — Nova Pharmaceuticals Australasia PT

What products does Nova Pharmaceuticals Australasia PT import from India?

Nova Pharmaceuticals Australasia PT imports 3 pharmaceutical products across 3 categories. Top imports: Betadine ($1.4M), Melatonin ($267.9K), Methylprednisolone ($257.0K).

Who supplies pharmaceuticals to Nova Pharmaceuticals Australasia PT from India?

Nova Pharmaceuticals Australasia PT sources from 8 verified Indian suppliers. The primary supplier is Marksans Pharma Limited (46.3% of imports, $4.7M).

What is Nova Pharmaceuticals Australasia PT's total pharmaceutical import value?

Nova Pharmaceuticals Australasia PT's total pharmaceutical import value from India is $2.0M, based on 57 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Nova Pharmaceuticals Australasia PT focus on?

Nova Pharmaceuticals Australasia PT imports across 3 categories. The largest: Brand Names & OTC Products (73.2%), Nutritional Supplements (13.7%), Corticosteroids (13.1%).

Get Full Nova Pharmaceuticals Australasia PT Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.